We retrospectively compared the outcomes and toxicities of melanoma brain metastases (MBM) patients treated with BRAF inhibitors (BRAFi) and stereotactic radiosurgery (SRS) with SRS alone. We identified 87 patients with 157 MBM treated with SRS alone from 2005 to 2013. Of these, 15 (17.2%) patients with 32 MBM (21.4%) received BRAFi therapy: three (20.0%) before SRS, two (13.3%) concurrent, and 10 (66.7%) after SRS. Overall survival (OS) was compared between cohorts using the product limit method. Intracranial outcomes were compared using cumulative incidence with competing risk for death. Baseline patient characteristics were similar between groups, except for the SRS cohort, which had higher rates of chemotherapy and more recent year of diagnosis. Radiation characteristics, including dose per fraction, total dose, gross tumor volume size, and prescription isodose, were also similar between cohorts. One-year outcomes -OS (64.3 vs. 40.4%, P = 0.205), local failure (3.3 vs. 9.6%, P = 0.423), and distant intracranial failure (63.9 vs. 65.1%, P = 0.450) were not statistically different between the SRS + BRAFi and SRSalone groups, respectively. The SRS + BRAFi group showed higher rates of radiographic radiation necrosis (RN) (22.2 vs. 11.0% at 1 year, P < 0.001) and symptomatic radiation necrosis (SRN) (28.2 vs. 11.1% at 1 year, P < 0.001).
Introduction
Over the past 10 years, the landscape for metastatic melanoma patients has changed significantly. Immune therapies, including antibodies targeting CTLA-4 and PD-1, have considerably improved overall survival (OS) [1] . Furthermore, 40-60% of melanoma patients also have a mutation in the serine protein kinasemost commonly V600Ethat leads to constitutive activation of the oncogene, leading to mutation-specific targeted therapies [2] ; prospective studies involving the use of these BRAF inhibitors (BRAFi), vemurafenib and dabrafenib (DAB), have reported remarkable response rates and improvements in OS [2] [3] [4] . Although immune therapy and BRAFi have shown improvements in extracranial efficacy, their benefit intracranially has been limited [3, 4] . As a result, these agents are often utilized with radiation to maximize intracranial control. Although whole-brain radiation therapy (WBRT) is the historical standard of care, two concerns for melanoma patients have arisen with this therapy: (a) as melanoma patients are living longer because of improvements in systemic therapy, neurocognitive toxicities from WBRT are more significant [5] and (b) melanoma is a radioresistant tumor; low dose per fraction WBRT may not provide adequate local control [6] . As a result, systemic agents, including BRAFi, are commonly being combined with stereotactic radiosurgery (SRS) for melanoma brain metastases (MBM) patients.
Recent studies, however, report potential concerns from treatment with radiation and BRAFi. A case report of a patient with metastatic melanoma treated with stereotactic body radiation for a liver lesion, followed by vemurafenib (VMF) 2 days later, led to significant skin necrosis and liver damage in the entrance radiation portal fields [7] . Another case report suggests that the combination is associated with radiation necrosis (RN) [8] . However, multiple studies have investigated the efficacy and toxicity of SRS and BRAFi, reporting no significant increase in side effects [9] [10] [11] [12] . Given the controversy between these studies, the aim of our project is to report our own institutional experience with SRS and BRAFi for MBM patients.
Methods

Patients
After receiving Institutional Review Board approval, we retrospectively identified 87 consecutive patients with MBM with a total of 157 brain metastases (BM) treated with SRS from 2007 to 2014.
The half-life of VMF and DAB is 40 h [13] and 8 h [14] , respectively. Assuming that it takes five half-lives to clear the drug [15] , we included patients treated with VMF 12 days before SRS or DAB 2 days before SRS. We also included patients treated concurrently or after SRS. Patients treated without a BRAFi were included in the SRS-alone group.
All patient charts were reviewed for the following baseline characteristics at the time of initial SRS: age, sex, clinical trial enrollment, number of brain metastases, presence of active systemic disease, primary controlled, Eastern Cooperative Group Oncology performance status, recursive partitioning analysis (RPA), melanoma specific graded performance assessment score, lactate dehydrogenase (LDH) value, previous systemic therapy, and next systemic therapy. Radiation treatment parameters were also recorded, including the number of fractions, dose per fraction, cumulative total dose, treatment to an intact metastasis or resection cavity, conformity index, prescription isodose line, cumulative gross tumor volume (GTV), and planning target volume (PTV) margin.
Radiation treatment
Technical details of SRS have been described previously [16, 17] . Briefly, SRS was delivered using a frameless linear accelerator-based radiosurgery unit with 6 MV photon beams. The T1 postcontrast MRI defined lesion constituted the GTV. No margin was used to create a clinical target volume. The GTV was expanded by 1 mm to generate the PTV. The radiation dose was prescribed on the basis of the size of the lesion and its proximity to other structures. Lesions up to 20 mm in diameter were treated to 21 Gy, 21-30 mm in diameter to 18 Gy, and 31-40 mm in diameter to 15 Gy. Patients with large lesions (typically > 40 mm in diameter) were treated with fractionated radiosurgery over three to five fractions using a frameless radiosurgery technique.
Follow-up
Post-SRS follow-up consisted of a clinical examination and brain MRI at 4-6 weeks, followed by clinical exam and MRI brain imaging every 3 months thereafter, unless clinically indicated at an earlier time point. Local recurrence (LR) was defined as the presence of new progressive nodular enhancement within a previous 80% isodose line of the previous SRS treatment. Distant intracranial failure (DIF) was defined as the presence of new enhancing lesions distinctly outside the previous SRS field.
Toxicity
Radiographic RN was defined as the development of a contrast-enhancing mass within previous SRS fields; if there was a question of the nodular enhancement representing LR versus RN, cases were discussed at a multidisciplinary tumor board to develop a consensus. Additional functional imaging was also obtained (e.g. magnetic resonance perfusion, magnetic resonance spectroscopy, or brain PET) to further aid evaluation. For patients who were symptomatic from these adverse events, steroids were initially used. In patients with continued symptoms, hyperbaric oxygen and/or bevacizumab were also considered, whereas surgery was reserved for refractory patients and/or where the diagnosis remained unclear. Patients who underwent salvage surgical resection were deemed to have an LR if there was evidence of any residual disease, whereas patients with only necrosis (and no residual disease) were considered to have RN.
Statistical analysis
The SRS-alone and SRS + BRAFi groups were compared across categorical covariates using χ 2 or Fisher's exact tests, where appropriate, and were compared across continuous variables using analysis of variance. For OS, death from any cause was defined as the event and patients were censored at the time of last follow-up. OS was estimated using the Kaplan-Meier product-limit method; the log-rank test was used to assess for differences between patients in the SRS-alone cohort and the SRS + BRAFi cohort. A univariate analysis and MVA was carried out using the Cox proportional hazards model.
Nonsurvival outcomes: LR, DIF, RN, and symptomatic radiation necrosis (SRN) were estimated using the cumulative incidence methodology, with death without the event considered a competing risk. For these intracranial outcomes, patients were censored at the time of last brain imaging or salvage WBRT, whichever came first. Cumulative incidence curves for each nonsurvival outcome were compared between groups with death as a competing risk using Gray's test for equality across groups [18] . Univariate and multivariable regression analyses using the semiparametric proportional hazards model in the presence of competing risks were carried out as proposed by Fine and Gray [19] . All potentially prognostic covariates that were statistically significant in the univariate analysis were entered into the multivariable model. All analyses were carried out using SAS, version 9.4.0 statistical software (SAS Institute Inc., Cary, North Carolina, USA). All statistical tests were two sided, with P-values less than 0.05 considered statistically significant.
Results
Patient characteristics
Of the 87 MBM patients identified, 15 (17.2%) received BRAFi. Fourteen of 15 (93.3%) patients in the BRAFi cohort were treated with VMF, with the other patient treated with DAB. Three patients (20.0%) received treatment before SRS, one patient (13.3%) received concurrent treatment with SRS, and 10 patients (66.7%) received BRAFi after SRS. The median time between SRS and BRAFi was 40 days. A total of 157 BM were treated, 125 (79.6%) with SRS alone and 32 with SRS + BRAFi (21.4%). Median imaging follow-up was 6.5 (0.4-152.3 months) and 18.9 months (2.13-152.3 months) for all patients and living patients at follow-up, respectively. Table 1 shows that the two groups were statistically similar, except for a higher rate of previous chemotherapy (P = 0.017), type of next systemic therapy (P < 0.001), and more recent year of diagnosis (P < 0.001) for the SRS + BRAFi cohort. The rates of immune therapies were similar between cohorts. Thirty-nine (44.8%) patients were treated for multiple BM. The SRS + BRAFi cohort had a trend toward lower rates of single metastases [(33.3 vs. 59.7%) P = 0.062] and melanoma specific graded performance assessment less than 3 [(53.3 vs. 26.4%) P = 0.063]. In terms of radiation treatment characteristics, patients in the BRAFi group did have a trend toward tighter PTV margin (93.8 vs. 76.2%, P = 0.057); there were no other differences in radiation parameters, including number of fractions, radiation dose per fraction,, cumulative GTV volume, and prescription isodose ( Table 1) .
Overall survival
No difference in OS was identified between the cohorts (P = 0.20) in univariate analysis. Six and 12-months OS for the SRS-alone and SRS + BRAFi groups are 72.8 vs. 78.6% and 40.4 vs. 64.3%, respectively ( Fig. 1 ). Univariate analysis showed LDH as the only statistically significant predictor for survival; however, this was not significant on MVA.
Intracranial control
Fifteen patients (17%) developed LR (Fig. 2 ). The median time to LR was 4.37 months (0-18 months). There was no difference in the rates of LR between the SRS + BRAFi and the SRS-alone cohorts (3.3 vs. 9.6% at 1 year, P = 0.43). Univariate analysis showed melanomaspecific GPA (P = 0.019), RPA (P < 0.001), and number of BM (P < 0.001) to be associated with improved LR-free survival. In addition, active systemic disease (P = 0.02) was associated with increased LR. On MVA, only the presence of two or more BM [hazard ratio (HR) = 0.10; 95% confidence interval (CI), 0.01-0.85; P = 0.035] and We also measured the initial radiographic response to therapy. The mean lesion size at the time of diagnosis was statistically similar between the SRS and the SRS + BRAFi cohorts: 13.18 vs. 9.57 mm, respectively. At 3 months after treatment, the mean lesion size decreased to 12.2 and 8.43 mm in the two groups. A statistically significant difference in the mean percentage change of lesion size was not found between the two groups: 12.2% for SRS vs 15.1% for SRS + BRAFi (P = 0.252). Figure 3 shows an example of a patient treated with SRS and the related changes to the two lesions in this patient. rates than the SRS-alone cohort (at 1 year: 28.2 vs. 11.1%, P < 0.001) ( Fig. 4 ). Of the eight SRS + BRAFi patients developing SRN, three received the BRAFi before SRS, one received it concurrently, and four received the BRAFi after SRS. Table 2 compares the basic side effect profile of the two groups.
The use of BRAFi was associated significantly with RN on univariate analysis (HR: 3.42; 95% CI, 1.68-6.98; P ≤ 0.001) and MVA (HR: 3.38; 95% CI, 1.32-8.66; P = 0.011) ( Table 3 ). Patients who had received previous chemotherapy had lower rates of RN on MVA (HR: 0.13; 95% CI, 0.02-0.97; P = 0.046).
Furthermore, on univariate analysis for SRN, BRAFi and active systemic disease were significant predictors. MVA confirmed the association between BRAFi (HR: 6.10; 95% CI, 2.37-15.70; P ≤ 0.001) and SRN. The presence of active systemic disease was associated with decreased SRN on univariate analysis (HR: 0.33; 95% CI, 0.11-0.95; P = 0.040) and showed a trend on MVA (HR: 0.34; 95% CI, 0.11-1.02; P = 0.054). No radiation parametersincluding cumulative radiation dose, number of fractions, GTV volume, nor marginwere found to be significant predictors for RN or SRN on MVA.
Discussion
As recent advances in systemic agents, including BRAFi and immune therapies, have improved OS in metastatic melanoma, measures to improve quality of life are becoming paramount. Although these newer therapies have shown extracranial efficacy, their intracranial potency is often limited by the blood-brain barrier. To overcome this, SRS is often combined with systemic therapies to provide intracranial and extracranial control, respectively. However, studies investigating the safety of these therapies in sequence are needed to verify that Change in the size of lesion 3 months after stereotactic radiosurgery. MRI, T1 before (top panels) and after (bottom panels) contrast. Images on the left are 3 months after treatment; images on the right are at the time of initial stereotactic radiosurgery. The lesion in the right temporal lobe is stable in size; the lesion in the left medial occipital lobe develops hemorrhage, as can be seen by increased intensity on T1 precontrast MRI scans. This patient was in the non-BRAF inhibitor cohort. RN is a late adverse side effect of SRS; treatment for symptomatic patients includes steroids, hyperbaric oxygen, bevacizumab, and/or surgical intervention. Although these treatments can be effective, they may result in significant morbidity. Methods to avoid excessive RN and related treatment are therefore crucial. Although preclinical studies suggest minimal penetration of the intact BBB by VMF [20] , radiation therapy has been shown to increase permeability of the BBB [21] . Therefore, a transient disruption in the BBB following radiation can potentially enhance the uptake of BRAFi, increase radiosensitivity, and theoretically exacerbate toxicities. In light of this and case reports showing an increased risk of RN, the current NCCN guidelines raise caution on the use of the combination of BRAFi and radiotherapy.
Four studies have suggested that the delivery of SRS and BRAFi is a regimen not associated with an increased risk of RN (Table 4 ). The first published study by Narayana et al. [11] reported on 12 patients treated with SRS and/or WBRT and VMF, with one patient developing RN; another series by Ahmed et al. [9] reported on 24 patients treated with only SRS and VMF and also found that one patient developed SRN that required surgery. Gaudy-Marqueste et al. [12] reported on 30 patients treated with SRS and BRAFi. Similar to our study, their BRAFi cohort included patients treated concurrently, after, or five halflives before SRS was delivered. These authors did show that 13.3% of lesions had a greater than 20% decrease in size; however, minimal toxicity was noted. From these three series, the rates of RN do appear low. Nevertheless, the rates of RN compared with a contemporaneous cohort of BRAFi alone or SRS alone remain unclear.
To directly compare the outcomes of patients and to account for differences in baseline characteristics, Ly et al. [10] reported on their institutional experience of SRS alone and SRS and BRAFi for MBM. The authors found that the BRAFi cohort was associated with a higher risk of hemorrhage, but they did not report on RN. Furthermore, all of these studies have used Kaplan-Meier statistics to determine rates of RN or adverse events; however, the cumulative incidence method with death as a competing risk for intracranial outcomes, including RN, has been suggested to be a more accurate model [18, 19] in the brain metastases population that has a high-risk of death within 1 year.
In this study, we attempted to directly compare our BRAFi patients with SRS to SRS alone. We first included patients treated with BRAFi before the drug was Rates of both adverse events are not statistically different between the two cohorts. BRAFi, BRAF inhibitor; SRS, stereotactic radiosurgery. potentially cleared (i.e. five half-lives) [13, 14] , during, or after completion of SRS. The median time between SRS and BRAFi in our study was 40 days. We then compared the incidence of RN in MBM patients treated with SRS and BRAFi with a cohort of SRS-alone patients. Using cumulative incidence model statistics, we found that BRAFi delivered in proximity to SRS was associated with significantly higher rates of SRN at 1 year (28.2 vs. 11.1%, P < 0.001); furthermore, the BRAFi cohort was a significant factor in univariate and multivariate analyses for SRN. Treatment cohorts had similar patient baseline characteristics, except that the non-BRAFi cohort had higher rates of previous chemotherapy. Chemotherapy has been suggested to increase the risk of RN [22] and as such may be a potentially confounding factor to our results. However, the non-BRAFi group received higher rates of chemotherapy, suggesting that this group may have higher rates of RN; this is in contrast to our result that the BRAFi group had higher SRN. Furthermore multiple prospective studies [23] [24] [25] and a large retrospective study [26] investigating predictors for RN showed that chemotherapy is not a predictor for radiographic nor SRN.
The SRS alone cohort did have more patients with margin higher than 2 mm; PTV margin expansion, which reflects the amount of normal irradiated brain tissue, is a known predictor for RN [26] . However, PTV margin higher than 1 mm was not a significant predictor for RN on univariate analysis (P = 0.296).
Although our study suggests that RN may be elevated with BRAFi treatment, one limitation is that we do not have a cohort of BRAFi alonewhich itself may cause intracranial toxicityto directly compare with. Two prospective trials have investigated BRAFi alone, the first with VMF (2) and the second with dabrafanib (4), with both showing no incidence of CNS grade 2 toxicities or higher. In light of these reports, we believe that our finding of SRS and BRAFi to be associated with RN is provocative.
Our study, however, has multiple limitations, including its retrospective design, small sample size, and nonrandomized cohorts, which could contribute toward selection bias. Another limitation of our study is the variety in treatment sequence and timing of delivery between treatments. Finally, distinguishing RN from LR can be quite challenging. The five patients requiring surgical resection highlight this: two were found to have pathologic evidence of RN only, whereas three had RN and locally recurrent tumor. The strengths of this study include its homogenous follow-up/surveillance schedule, statistical model accounting for the cumulative incidence of the outcome with death as a competing risk, and the use of multivariate analysis to adjust for potential confounding variables.
Conclusion
Our retrospective institutional experience use of BRAFi with SRS was not associated with improved survival or intracranial control. Furthermore, patients treated with this regimen developed increasing rates of RN and SRN. Prospective studies investigating BRAFi therapy and SRS for MBM should consider incorporating methods to decrease potential RN in high-risk patients, including fractionated radiosurgery [27] or preoperative radiosurgery [28] . 
